Chronic Kidney Disease

The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.

Latest News

Patient telling physician about his pain and health problems during visit to hospital. Young African-American man complaining about back ache while sitting on examination bed at the doctor's - Studio Romantic - stock.adobe.com.jpeg
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment

April 21st 2025

An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.

Center on Health Equity and Access
Health Equity & Access Weekly Roundup: April 21, 2025

April 21st 2025

Image credit: health care costs - Nuttapong punna
Cost-Effectiveness Analysis: CKD Screening, SGLT2 Inhibitors Can Reduce Kidney Failure Risk, Racial Disparities

April 18th 2025

Pharmacy online_evso - adobe.stock.com
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps

April 15th 2025

Healthcare costs and fees concept.Hand of smart doctor used a calculator for medical costs in modern hospital - everythingpossible - stock.adobe.com.jpeg
National Data Show Rising Risk, Cost of CKD in Patients With Acute Myocardial Infarction

April 10th 2025

Population Health Management of Chronic Kidney Disease (CKD)

An expert panel discusses chronic kidney disease (CKD), its impact on cardiovascular disease, and the methods of treatment used on the patient populations.

Panel members

More News

Caring for Individuals With Kidney Disease During the Pandemic
January 20th 2021

Caring for Individuals With Kidney Disease During the Pandemic

Mary Dittrich, MD
Nephrologist Mary Dittrich, MD, the chief medical officer and executive vice president of U.S. Renal Care as well as cofounder and partner of Boise Kidney & Hypertension Institute, discusses how to keep patients safe while providing high-quality kidney care during the coronavirus disease 2019 pandemic.
Graphic depicting lineage
January 16th 2021

Family History, Genetics May Help to Predict, Detect Early-Stage CKD

Skylar Jeremias
A population-based study from the Netherlands showed that individuals with had at least 1 direct relative affected with chronic kidney disease (CKD), suggesting that biomarkers for CKD can aid in detecting the early stages of the disease.
Kidney graphic
January 8th 2021

FDA Grants Priority Review to Dapagliflozin for CKD

Skylar Jeremias
The FDA decision on dapaglifozin for CKD is expected in the second quarter of 2021.
Large Swedish Study Says Stopping RAS Inhibitors Leads to Worse CKD Outcomes
January 3rd 2021

Large Swedish Study Says Stopping RAS Inhibitors Leads to Worse CKD Outcomes

AJMC Staff
A new study from Sweden cautions against routine discontinuation of renin-angiotensin system (RAS) inhibitors in patients with chronic kidney disease (CKD).
Dr Guofen Yan Considers Strategies for Improving CKD Outcomes in Minority Populations
December 31st 2020

Dr Guofen Yan Considers Strategies for Improving CKD Outcomes in Minority Populations

Slowing progression of chronic kidney disease can help mitigate adverse outcomes in minority populations, said Guofen Yan, PhD, associate professor of biostatistics in the Department of Public Health Sciences at the University of Virginia School of Medicine.
Dr Kunihiro Matsushita Lays Out the Benefits of the CKD Patch Approach
December 31st 2020

Dr Kunihiro Matsushita Lays Out the Benefits of the CKD Patch Approach

This approach allows clinicians to keep using existing prediction models and incorporate chronic kidney disease (CKD) data seamlessly to calibrate patients' risks, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.
Top 5 Most-Read Chronic Kidney Disease Articles of 2020
December 28th 2020

Top 5 Most-Read Chronic Kidney Disease Articles of 2020

Allison Inserro
Two story lines predominated renal news in 2020: coronavirus disease 2019's effect on the kidneys and the overwhelming benefits of sodium-glucose cotransporter 2 inhibitors for those with chronic kidney disease and type 2 diabetes.
Contributor: How Payers Can Be Effective in New Value-Based Models for CKD
December 26th 2020

Contributor: How Payers Can Be Effective in New Value-Based Models for CKD

Precision Value & Health Ryan Cox
The author discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patienst with chronic kidney disease (CKD).
Virtual Platform Allows Transplant Evaluations, Wait-Listing to Continue Despite Pandemic
December 26th 2020

Virtual Platform Allows Transplant Evaluations, Wait-Listing to Continue Despite Pandemic

Skylar Jeremias
A study evaluating whether a virtual platform can improve access to evaluations for kidney transplants found that surgical teams could continue to keep up with evaluations adding patients to wait lists during the pandemic.
Researchers Discuss Closing Racial Gaps in ESKD Incidence Rates
December 19th 2020

Researchers Discuss Closing Racial Gaps in ESKD Incidence Rates

Bringing together genetic work with social determinants of health can improve understanding of factors associated with ESKD disparities, said Adriana Hung, MD, MPH, associate professor of medicine at Vanderbilt University, and Bryce Rowan, a statistical genetic analyst.
Study Describes Early Benefit, Effectiveness of RASi for CKD
December 18th 2020

Study Describes Early Benefit, Effectiveness of RASi for CKD

Larry Hanover
An observational study showed that it may be more effective to start patients on a renin-angiotensin system inhibitor (RASi) than a calcium channel blocker in delaying progression of advanced kidney disease.
Study Shows Effect of COVID-19 on Hospitalization Risk in CKD
December 12th 2020

Study Shows Effect of COVID-19 on Hospitalization Risk in CKD

AJMC Staff
Patients with COVID-19 and end-stage renal disease were 11 times more likely to be admitted to the hospital than patients without kidney disease.
Dr George Bakris
December 12th 2020

Dr George Bakris on Discontinuation Rates, CV Outcomes of FIDELIO-DKD

A variety of factors contributed to discontinuation rates in FIDELIO-DKD, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
Study Examines Clinical Implications of Removing Race From eGFR in CKD
December 4th 2020

Study Examines Clinical Implications of Removing Race From eGFR in CKD

Allison Inserro
As higher estimated glomerular filtration rate (eGFR) equations indicate better kidney function, there has been increasing recognition that this may lead to inequitable and delayed care in treating chronic kidney disease (CKD) in Black adults.
Dr Jill Krissberg on Addressing Racial Disparities in Glomerular Disease
December 3rd 2020

Dr Jill Krissberg on Addressing Racial Disparities in Glomerular Disease

Making sure patients have a strong medical home and close follow-up is one way to reduce glomerular disease disparities among children, said Jill Krissberg, MD, a pediatric nephrology fellow at Stanford University School of Medicine.
Contributor: The Wrong Way to Design a Medicare Mandatory Demonstration
November 27th 2020

Contributor: The Wrong Way to Design a Medicare Mandatory Demonstration

Jackson Williams, JD
Jackson Williams is vice president, public policy at Dialysis Patient Citizens. Previously he worked at the Centers for Medicare and Medicaid Services (CMS); was a health services researcher in the AARP Public Policy Institute; and a lobbyist on health policy issues for 3 nonprofit associations. His more than 2 decades of experience monitoring, studying, and overseeing federal demonstration projects include time as a project officer at CMMI and serving as the consumer representative on a Medicare pilot site’s governing body.
Dr George Bakris Discusses Next Steps for Finerenone
November 27th 2020

Dr George Bakris Discusses Next Steps for Finerenone

If results from FIGARO-DKD are as positive as those of FIDELIO-DKD, the field will work aggressively to get the message out, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
Dr George Bakris Speaks About Increasing Minority Representation in CKD Trials
November 21st 2020

Dr George Bakris Speaks About Increasing Minority Representation in CKD Trials

In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
Even in Advanced CKD, Canaglifozin Slows Rate of Kidney Decline, Study Says
November 19th 2020

Even in Advanced CKD, Canaglifozin Slows Rate of Kidney Decline, Study Says

Allison Inserro
A new analysis of CREDENCE data showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor worked in advanced disease and without causing acute kidney injury.
Dr Rajiv Agarwal on the Future of Finerenone
November 13th 2020

Dr Rajiv Agarwal on the Future of Finerenone

The FIDELIO-DKD program is perhaps just the beginning of seeing how finerenone can be used, said Rajiv Agarwal, MD, MS, FASN, a professor of medicine at Indiana University School of Medicine and a staff physician at the Veterans Affairs Medical Center in Indianapolis, Indiana.
Site Logo
November 11th 2020

Primary Care Referrals to Nephrology in Patients With Advanced Kidney Disease

Ajay Dharod, MD Richa Bundy, MPH Gregory B. Russell, MS William Y. Rice III, MD Cameron E. Golightly, DO Gary E. Rosenthal, MD Barry I. Freedman, MD
Primary care physicians did not refer the majority of patients with severe nephropathy to specialists; nonreferred patients had fewer comorbidities and might be better kidney transplant candidates.
kidneys
November 5th 2020

The Kidney Community Advances Innovative Solutions and Improves Patient Care—Even During a National Pandemic Crisis

Anupam Agarwal, MD, FASN John P. Butler
Authors from the American Society of Nephrology and Kidney Care Partners discuss the response of the kidney care community to the COVID-19 pandemic.
Dr Joshua Rein Discusses the Next Steps of Cannabis Treatment for Kidney Disease
October 31st 2020

Dr Joshua Rein Discusses the Next Steps of Cannabis Treatment for Kidney Disease

The federal illegality and Schedule I listing of cannabis significantly impair our ability to conduct any kind of prospective clinical research, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.
Stethoscope on US flag
October 30th 2020

Research Highlights Impact of SDOH on Veterans With CKD

Gianna Melillo
A pair of abstracts presented at Kidney Week 2020 underscore the relationship between social determinants of health (SDOH) and chronic kidney disease (CKD) in military populations and the challenges of tracking these factors.
Jardiance
October 24th 2020

Empagliflozin Cuts Risk of CV, Kidney Events in Heart Failure Regardless of CKD Status

Mary Caffrey
New results from EMPEROR-Reduced presented at Kidney Week 2020.
Nkinsi
October 16th 2020

UW Medical Students Force Change to Key Kidney Measure to End Disparity

Mary Caffrey
Prompted by students, the medical school overturned a longstanding diagnostic protocol that was not well-founded in evidence.
dialysis
October 14th 2020

Dialysis Is on the Ballot Again in California

AJMC Staff
For-profit dialysis centers are spending heavily to defeat the measure.
blood pressure cuff
October 10th 2020

Surgeon General Issues Call to Action on Hypertension

Mary Caffrey
The recent focus on disparities in health care comes through in the call to action.
Dapagliflozin Gets Breakthrough Therapy Designation for CKD
October 2nd 2020

Dapagliflozin Gets Breakthrough Therapy Designation for CKD

Mary Caffrey
The FDA action follows presentation of results in August during the European Society of Cardiology 2020 Virtual Congress.
New VERTIS-CV Analysis Finds Renal Benefits for Ertugliflozin on Par With Other SGLT2s
September 29th 2020

New VERTIS-CV Analysis Finds Renal Benefits for Ertugliflozin on Par With Other SGLT2s

Mary Caffrey
A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.
<1
...
45678910111213>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo